Literature DB >> 27993797

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.

F Gelsomino1, G Vitale2, A D'Errico3, C Bertuzzi3, P Andreone2, A Ardizzoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27993797     DOI： 10.1093/annonc/mdw649

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  25 in total

Review 1.  A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.

Authors:  Francesco Gelsomino; Giovanni Vitale; Andrea Ardizzoni
Journal:  Invest New Drugs       Date:  2017-06-20       Impact factor: 3.850

Review 2.  Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Authors:  Jordi Remon; Laura Mezquita; Jesús Corral; Noelia Vilariño; Noemi Reguart
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.

Authors:  Hisato Kawakami; Junko Tanizaki; Kaoru Tanaka; Koji Haratani; Hidetoshi Hayashi; Masayuki Takeda; Ken Kamata; Mamoru Takenaka; Masatomo Kimura; Takaaki Chikugo; Takao Sato; Masatoshi Kudo; Akihiko Ito; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2017-03-20       Impact factor: 3.850

4.  Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.

Authors:  Emanuel Raschi; Alessandra Mazzarella; Ippazio Cosimo Antonazzo; Nicolò Bendinelli; Emanuele Forcesi; Marco Tuccori; Ugo Moretti; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 5.  [Liver injury induced by immune checkpoint inhibitor-therapy : Example of an immune-mediated drug side effect].

Authors:  B K Straub; D A Ridder; A Schad; C Loquai; J M Schattenberg
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

Review 6.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

7.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.

Authors:  Camila C Simoes; Swan N Thung; Maria Isabel Fiel; Max W Sung; Myron E Schwartz; Stephen C Ward
Journal:  Mod Pathol       Date:  2020-09-28       Impact factor: 7.842

Review 9.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.